The FINTECH GIMV FUND is a Japan focused venture capital fund backed primarily by FGI, Gimv NV, Belgium’s largest private equity investment firm, and the Development Bank of Japan. Since its establishment in December 2007, the fund has maintained an investment focus on companies with high growth potential in technology-oriented sectors, especially information and communications technology, new materials and life sciences. Key portfolio companies in the fund are described below.
Investment since July 2012
Histogenics is involved in the business of regenerative medicine for neocartilage replacement to repair articular damage to the knee caused by sports injuries, accidents or other orthopedic conditions. The company is listed on the NASDAQ market—HSGX—in the United States.
Oree Inc. (Ramat Gan, Israel)
Investment period March 2011 ～2015
Oree focuses on LED planar lighting, applying proprietary light guides and light element mounting technology to develop and market LED modules with thin and uniformly illuminating surfaces. Oree sells the product for general lighting purpose as a fabless company.
mofiria Corporation (Tokyo, Japan)
Investment since March 2011
Seeking to realize a society that is safe, secure and enjoyable, Mofiria develops, manufactures and markets identification systems using finger vein authentication technology to deliver compact, fast yet accurate authentication, and comfort in the operability of mobile devices. The company's proprietary "mofiria" finger vein authentication technology is sold to customers worldwide.
Whizzy Corporation (Tokyo, Japan)
Investment since June 2010
To boost business results through various social media, an increasingly integral component of online marketing, Whizzy provides services, from strategy plannings to system development and execution, to help optimize social media marketing for the client.
SFJ Pharmaceuticals Inc.( California, United States)
Investment since February 2010
SFJ Pharmaceuticals is a Specialty Pharma Company deploying a new business model for the clinical development and registration of pharmaceutical products in Japan. The company provides a financially advantageous and creative alternative approach to partnering in Japan.
To date, the company has partnered with several major pharmaceutical companies, including Eisai Co., Ltd., under a collaborative development agreement. Joint development of a therapy for thyroid cancer ended on a successful note in 2015.
Currently, several cancer treatment development projects are in Phase III clinical trials.
iPierian Inc. (California, United States)
Investment period since July 2009～2014
iPierian is the first company to apply cellular reprogramming and directed differentiation to cells that are derived from patients representing a broad spectrum of diseases. iPierian will apply its technology to recapitulate human disease in vitro, enabling the discovery of novel targets and disease-modifying therapeutics. In April 2014,Bristol-Myers Squibb Company(NYSE:BMY) acquired iPierian,Inc.
Intellikine (California, United States)
Investment period June 2009～January 2012
Intellikine is a privately-held clinical stage company focused on discovery of innovative small molecule drugs targeting PI3K/mTOR pathway. In just three years from the founding, the company has discovered and advanced one of the leading pipelines of drug candidates targeting this important pathway.
In January 2012, Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) acquired Intellikine.
RI Co., Ltd. (Tokyo, Japan)
Investment since March 2009
Established in 2005, RI is one of Japanese very few utility software makers. It has successfully cultivated sales channels to corporate customers, culminating in software installation at 700 companies and 20,000 licenses sold.
RI try to penetrate the consumer market with stand-alone software in September 2011.
The company’s backup software products enjoy a high market profile.
ASOCS Ltd. (Rosh HaAyin, Israel)
Investment since September 2008
ASOCS is a fabless LSI design company for wireless LSI. Its forte is in reconfigurable processors which facilitate changes to as yet non-standardized protocols and multiple protocol switches while meeting small size and low power consumption requirements.
Trius Therapeutics (California, United States)
Investment since March 2008
This biopharmaceuticals company focuses on the discovery and development of antibiotics to treat serious, life-threatening infections. The company was enrolled in Phase 3 clinical trials for tedizolid phosphate used in the treatment of bacterial infections caused by methicillin-resistant Staphylococcus aureus.
Trius Therapeutics listed on NASDAQ in August 2010.
In September 2013,Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) completed acquisition of Trius Therapeutics, Inc.